• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

MediGene

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · May 31, 2011

MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene's AAVLP Platform

Examination of product candidates for the prevention of HPV-associated diseases Martinsried/Munich, May 31, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) and The Johns Hopkins …

News · May 18, 2011

MediGene Signs Veregen® Commercialization Agreement with SynCore Bio in Taiwan

Martinsried/Munich, May 18, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) has signed an exclusive license and supply agreement with SynCore Bio, a subsidiary of the Sinphar Group, …

News · May 13, 2011

MediGene Reports Profit for the First Three Months of 2011

- Increase in revenue (from continued and discontinued operations) to EUR 27.9 million (Q1 2010: EUR 12.0 million) - Positive EBITDA result of EUR 19.2 million (Q1 2010: EUR -2.4 million) - Net profit …

News · March 10, 2011

MediGene and Will-Pharma Sign Agreement for the Commercialization of Veregen® in Benelux

Martinsried/Munich, March 10, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) has signed an exclusive license and supply agreement with Will-Pharma for the commercialization and …

News · January 25, 2011

MediGene Adds Romania and Bulgaria to Existing Partnership Agreement with Meditrina for the Commercialization of Veregen®

Martinsried/Munich, January 25, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) announced today that its existing partnership with Meditrina Pharmaceuticals Ltd., Greece, for the …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact